Cover Image
市場調查報告書

Agios Pharmaceuticals, Inc.:產品平台分析

Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253798
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Agios Pharmaceuticals, Inc.:產品平台分析 Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年10月21日 內容資訊: 英文 37 Pages
簡介

Agios Pharmaceuticals, Inc.ha,是在癌症代謝的領域開發治療藥的生物製藥公司。該公司進行以癌症的治療、糖解、脂肪酸的代謝、自吞噬作用為焦點的藥物的開發。該公司產品使用在自體免疫性、發炎性、神經系統的各疾病的治療上。

本報告提供Agios Pharmaceuticals, Inc.的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關最新的新聞和發表、正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等。

Agios Pharmaceuticals, Inc.的基本資料

  • Agios Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Agios Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Agios Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Agios Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Agios Pharmaceuticals, Inc.:藥物簡介

  • AG-120
  • AG-348
  • AGI-14100
  • CM-4
  • Small Molecule to Inhibit PKM2 for Cancer
  • Small Molecules For Inborn Errors Of Metabolism
  • Small Molecules to Inhibit Glutaminase for Cancer

Agios Pharmaceuticals, Inc.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Agios Pharmaceuticals, Inc.:最近的開發平台趨勢

Agios Pharmaceuticals, Inc.:暫停中的計劃

Agios Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07675CDB

Summary

Global Markets Direct's, 'Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Agios Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Agios Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Agios Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Agios Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Agios Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Agios Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Agios Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Agios Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Agios Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agios Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Agios Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Agios Pharmaceuticals, Inc. Snapshot
    • Agios Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Agios Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Agios Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Agios Pharmaceuticals, Inc. - Pipeline Products Glance
    • Agios Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Agios Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Agios Pharmaceuticals, Inc. - Drug Profiles
    • AG-348
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-881
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGI-14100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CM-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate PKM2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inborn Errors Of Metabolism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Glutaminase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Agios Pharmaceuticals, Inc. - Pipeline Analysis
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Target
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Agios Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Agios Pharmaceuticals, Inc. - Dormant Projects
  • Agios Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Agios Pharmaceuticals, Inc., Key Information
  • Agios Pharmaceuticals, Inc., Key Facts
  • Agios Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Agios Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Agios Pharmaceuticals, Inc. - Phase II, 2015
  • Agios Pharmaceuticals, Inc. - Phase I, 2015
  • Agios Pharmaceuticals, Inc. - Preclinical, 2015
  • Agios Pharmaceuticals, Inc. - Discovery, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Agios Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Agios Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Agios Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top